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Current chemotherapy regimens have unsatisfactory results in most advanced solid tumors. It is therefore imperative to devise
novel therapeutic strategies and to optimize selection of patients, identifying early those who could beneﬁt from available
treatments. Mouse models are the most valuable tool for preclinical evaluation of novel therapeutic strategies in cancer and,
among them, patient-derived xenografts models (PDX) have made a recent comeback in popularity. These models, obtained by
direct implants of tissue fragments in immunocompromised mice, have great potential in drug development studies because they
faithfully reproduce the patient’s original tumor for both immunohistochemical markers and genetic alterations as well as in terms
of response to common therapeutics They also maintain the original tumor heterogeneity, allowing studies of speciﬁc cellular
subpopulations, including their modulation after drug treatment. Moreover PDXs maintain at least some aspects of the human
microenvironment for weeks with the complete substitution with murine stroma occurring only after 2-3 passages in mouse and
represent therefore a promising model for studies of tumor-microenvironment interaction. This review summarizes our present
knowledge on mouse preclinical cancer models, with a particular attention on patient-derived xenografts of non small cell lung
cancer and their relevance for preclinical and biological studies.
1.Introduction
Thecontinuouslygrowingbodyofknowledgeaboutmolecu-
lar events driving oncogenesis has led to the identiﬁcation of
newpotential targets fortherapy and hasconsequentlypaved
the way for the design of targeted compounds, oﬀering po-
tential new tools to improve the clinical outcome of cancer
patients. The therapeutic eﬃcacy of this large number of
new compounds compared to standard treatments (or in
association with them) has to be ultimately assessed through
clinical trials [1] but drug development process includes
many steps and requires investments both in time and
resources as well as the recruitment of patients who agree to
take part in human clinical trials. Typically, the developmen-
tal plan for a cancer chemotherapy agent involves sequential
s t e p ss u c ha sin vitro studies to identify the basic properties
of the compound; rodent studies to assess its potential
activity; pharmacology studies to deﬁne drug absorption,
distribution, metabolism, and elimination; toxicology stud-
ies to deﬁne a starting dose for humans [2]. The most
expensive steps are associated with preclinical toxicology and
pharmacology studies and for this reason it is of primary
importance to recognize early in the process compounds
unworthy of further development. Many diﬀerent in vitro2 Journal of Biomedicine and Biotechnology
assays have been used to identify lead compounds as
exempliﬁed by the 60 human tumor cell line anticancer drug
screen (NCI60) developed by the US National Cancer In-
stitute in the late 1980s as an in vitro drug discovery tool
which has proved valuable for high-throughput screens and
initial assessment of novel compounds. The subsequent
eﬃcacyassessmentinrodents,however,playsacrucialrolein
identifying those drugs which deserve further development.
In fact,compounds that showed some activities as anticancer
drugs on the NCI60 panel must undergo in vivo studies to be
presented to the Drug Development Group as candidates for
NCI development or licensing [3] highlighting the need for
animal models that closely recapitulate human disease for
eﬃcient drug development.
2. Mouse PreclinicalCancer Models
In general the reliability of rodent-based preclinical cancer
models can be questioned because of their imperfect corre-
lation with human clinical outcomes [4]. However, although
some drugs that show activity against human tumor xeno-
grafts (XGs) have failed to show activity in human clinical
trials, many of the clinically approved drugs in use today
have demonstrated and continue to demonstrate activity
in a variety of preclinical models [4–7]. In addition, it is
noteworthy to remember that mouse models are the most
valuable tool for preclinical evaluation of novel therapeutic
strategies in cancer primarily because humans and mice
are genetically closely related and consequently the major
signaling pathways are conserved between the two species.
The mouse is also small and relatively inexpensive to breed
and house. Moreover, the mouse germ line can be modiﬁed
to generate many diﬀerent mouse strains modeling diﬀerent
aspects of cancerogenesis. In the early 1980s, immunolog-
ically compromised mice, capable of supporting growth of
human tumors, became more widely available [8], resulting
in the development of human tumor xenografts models
whichrepresent,togetherwithgeneticallyengineeredmodels
(GEMs), the main categories of preclinical cancer models
used for current preclinical eﬃcacy studies. Distinct advan-
tages and disadvantages of the diﬀerent models are summa-
rized in Table 1.
2.1. Genetically Engineered Mice (GEMs). A genetically mod-
iﬁed mouse is a mouse whose genome has been altered by
genetic engineering techniques. The genome of these mice is
altered in genes known to be involved in malignant trans-
formation, that can be mutated, deleted, or overexpressed;
subsequently, the eﬀect of altering these genes is studied over
time to evaluate the eﬀect on tumorigenesis (both sponta-
neous or induced) and eventually therapeutic responses may
be followed in vivo [9–11].
There are two basic technical approaches to produce
genetically modiﬁed mice. The ﬁrst involves pronuclear
injection into a single cell of the mouse embryo, where it will
randomlyintegrateintothemousegenome[12]generatinga
transgenic mouse. The second approach involves modifying
embryonic stem cells with a DNA construct containing
DNA sequences homologous to the target gene [13]. This
method is used to manipulate a single gene, in most cases
“knocking out” the target gene, although more subtle ge-
netic manipulation can occur (e.g., only changing single
nucleotides).
The peculiar features of GEMs (germline alterations)
make them particularly suitable to follow tumor develop-
ment from early time points. Moreover, the development of
a tumor resembling the human counterpart in a genetically
modiﬁedmousecanbeveryusefulforreﬁnedstudiesofrela-
tionshipwiththemicroenvironment,thatcanalsobemanip-
ulatedinmicetroughspeciﬁcgeneticmanipulationsorusing
bone marrow transplantation. Furthermore, the possibility
to cross GEMs with other inbred mice strains provides the
opportunity to investigate the role of diﬀerent genetic
alterations in tumor development. It should however be
stressed that GEMs tumors are murine tumors and although
they might present characteristics closely resembling the hu-
man counterpart, they could never fully recapitulate a hu-
man tumor [14, 15]. Moreover, the number of modiﬁed
genes is usually too limited to be representative of the
heterogeneity of human solid tumors and the development
of a genetically modiﬁed mouse strain is very costly and time
consuming.
2.2.MouseXenograftModels. Xenotransplantation isdeﬁned
as any procedure that involves the transplantation of living
cells, tissues or organs from one species to another.
The growth of human tumors in a diﬀerent species (e.g.,
mouse) requires immunodeﬁciency in the host animal to
prevent rejection of the transplanted foreign tissues. There
are many strains of genetically determined immunodeﬁcient
mice containing single mutations (e.g., nude, scid, beige, xid,
rag-1 null, rag-2 null) or combined mutations, (e.g., bg/nu,
bg/nu/xid, nude/scid, nod/scid) available for cancer research
[16–18]. These strains have diﬀerent immunological impair-
ment and the availability of more permissive mouse strains
can strongly increase the eﬃciency of xenotransplantation;
however severely immunocompromised mice also have a
higher cost and their manipulation can be extremely de-
manding requiring controlled husbandry environment and
highly trained personnel. It is therefore mandatory to choose
the immunocompromised strain with the best “eﬃciency of
transplantation/costs” ratio for each application.
Successfulxenograftingofhumantumorsintonudemice
was ﬁrst reported in the late 1960s [19, 20]. Nude mouse
models are now extensively used in the development of po-
tential anticancer drugs and studies of tumor biology and
mice with severe combined immunodeﬁciencies (e.g., SCID,
beige, xid) have widened the spectrum of possible models
and enabled engraftments of human tumors that were pre-
viously diﬃcult to implant.
Tumor xenograft (XG) models can be broadly derived
either from the injection in immunocompromised mice of
human established tumor cell lines or from direct implant
of patient’s tumor fragments. This latter model has been
referred to by diﬀerent researchers as “tumorgraft,” “pri-
mary-tumor xenograft,” or “patient-derived xenograft” toJournal of Biomedicine and Biotechnology 3
Table 1: Main advantages and disadvantages of GEM, XG, and PDX mouse models.
Advantages Disadvantages
Genetically engineered mice
(GEM)
(i) Studies on deﬁned mutations
(ii) Possibility to follow tumor development from
early time points
(iii) Tumor microenvironment is representative of
the studied tumor
(iv) Potential analysis of eﬀects of mutations in
many genetic backgrounds by using a variety of
mouse strains
(i) Limited number of genes (usually not
representative of the heterogeneity of the tumor)
(ii) Development costly and time consuming
(iii) Tumor development in animals slow and
variable
(iv) Both, tumor and microenvironment are
murine
Xenograft
(XG)
(i) Allows a rapid analysis of response to a
therapeutic regimen
(ii) Source of material virtually unlimited for
immortal cell lines
(iii) Can predict drug response of human patient’s
tumor
(i) Human tumor microenvironment is not
represented
(ii) Orthotopic implant is often technically
complicated
(iii) Cells can undergo genetic modiﬁcation as
well as subpopulation rearrangements when
cultured
Patient-derived xenograft
(PDX)
(i) Provides a realistic representation of the
heterogeneity of tumor cell subpopulations
(ii) Can predict drug response of human patient’s
tumor
(iii) Stromal component is representative of the
parental tumor in the initial passages
(i) Orthotopic implant is often technically
complicated
(ii) Surgical fragments must be processed rapidly
(iii) Limited source of original material
point out the diﬀerence from conventional “xenografts”
generally intended as injection of suspensions of tumor cell
lines. For clarity throughout this paper we will refer to the
implantation of patient’s tumor fragments as “patient-
derived xenograft” (PDX), while the whole cohort of mice
carrying the expansion of tumor fragments derived from the
same patient will be deﬁned as “xenopatients” (XP).
In general, established tumor cell lines have a much
higher take rate when inoculated as a suspension into nude
mice than human solid tumors of the same histological type
that are transplanted directly from the patient [21]. On the
other hand, culturing tumor cells could lead to changes in
gene expression [22]a sw e l la sr e a r r a n g e m e n t si nt h ec o m -
position of the cellular populations that constitute the
original human tumor resulting in the xenotransplant of
a cellular population that is not fully representative of the
original tumor heterogeneity. Moreover, studies on XGs of
human cell lines to test drug responses do not often correlate
withclinicalactivityinpatients[23],especiallywhencellsare
injected subcutaneously. By contrast, when cells are used as
an orthotopic XG, there is a stronger predictive response
value, especially when a clinically relevant drug dosage is
used [23–25].
Implantation of either cells or tumor fragments is usu-
ally performed subcutaneously rather than orthotopically,
because of the technical diﬃculties often encountered in
these assays. This can raise doubts about the development of
tumor vasculature and tumor-stroma interactions compared
to those observed in the human tumor of origin. Interest-
ingly, as will be discussed more in detail later in this paper,
PDXs maintain the whole structure of the human parental
tumor during the initial passages in mouse making them
suitable also for microenvironment studies.
3.Patient-DerivedXenografts
Direct implantation of small tumor fragments in immuno-
compromised mice can result in growth of patient-derived
xenografts that accurately reproduce the heterogeneity of
human cancers, especially if a large set of a diﬀerent tumor
subtypesisavailable.Thesemodelscanbeseriallypropagated
in mice by subsequent passaging as tissue explants and
the use of standardized procedures for the assessment of
therapeutic eﬃcacy of diﬀerent drugs using PDXs allows a
rapid evaluation of combined therapies on a relatively large
set of tumors. However, in order to be relevant as a useful
tool for preclinical studies, a PDX panel should accurately
reproduce human cancers representing their various subcat-
egories and a particular PDX should accurately reproduce
the original patient’s tumor. Furthermore, there should be
a high correlation between preclinical and clinical results in
terms of therapeutic eﬃcacy, with the gold standard being
represented by PDXs that closely mimic (or even predict)
the clinical response of the patient’s tumor they derive from.
All these features have been recently investigated in PDXs
from diﬀerent human tumors resulting in the observation
that PDXs might represent a suitable model for preclinical
studies intended as a “quick” evaluation of the response to
diﬀerent therapeutic treatments. Although the rapidity of
this kind of approach is relative, being dependent on the
rate of implant of the tumor, it can nonetheless give very
relevant information in diﬀerent clinical settings. On the
one hand, while the models are being established and the
patients are undergoing ﬁrst-line treatment, it is possible to
acquire proof-of-concept information on relative sensitivity
or resistance to the diﬀerent regimens to be correlated with
the molecular features of the PDXs, while on the other it is4 Journal of Biomedicine and Biotechnology
possible to imagine an immediate clinically relevant use of
these models in selecting the best second line treatment for a
speciﬁc patient.
Hidalgo et al. recently reported their results obtained
with various advanced solid tumors resected from 14 pa-
tients, propagated in immunodeﬁcient mice, and treated
with 63 drugs in 232 treatment regimens. They showed an
overall remarkable correlation between drug activity in the
model and clinical outcome, both in terms of resistance and
sensitivity. Their results emphasize the relevance of PDX
panels in preclinical studies of anticancer treatments. The
treatmentstheyselectedforeachpatient,basedontheresults
obtained with the correspondent PDX, would not have
been the ﬁrst choice for a second- or third-line treatment,
nonetheless the objective response rate they obtained was
88% for treatments deemed eﬀective by the model and tested
in the patient, with 11 of 14 patients achieving a partial
response. This work highlights that personalized PDXs can
be used to investigate drug response with the ﬁnal aim to
select best personalized treatments to increase the response
rate of the patients [26].
Another preclinical setting in which PDXs can be
extremely relevant is represented by the evaluation of the
potentialofnewdrugsincancertreatment.Takingadvantage
from a panel of PDX which faithfully represents the hetero-
geneity of a cancer type, new drugs can be tested and can
lead to the identiﬁcation of the best treatment regimen for a
speciﬁc subtype of tumor as well as to the identiﬁcation of
new biological pathways involved in the development of the
tumor.
Encouraging results, which emphasize the potential of
this kind of preclinical model, were recently obtained with
metastatic colorectal cancer (mCRC) by Bertotti et al. that
established a large PDX cohort from 85 patient-derived
mCRC samples. Firstly, they validated the robustness of
the cohort of xenopatients showing that they responded to
the anti-EGFR antibody Cetuximab with analogous rates
compared to those observed in the clinic. Then, they strat-
iﬁedtheirPDXsinrespondersandnonrespondersandfound
an enrichment of tumors with HER2 ampliﬁcation in Cetux-
imab-resistant KRAS/NRAS/BRAF/PIK3CA wild-type cases
(36% versus 2.7% in unselected tumors). This approach
allowed them to discover that inhibition of HER2 in com-
bination with anti-EGFR antibodies induced overt, long-
lasting tumor regression in Cetuximab-resistant colorectal
cancers, an observation worthy of further clinical investiga-
tion [27].
Cetuximab response was also investigated in 79 diﬀerent
PDXs generated from colon, gastric, head and neck, lung
and mammary cancer, leading to the identiﬁcation of MET
activation as a mechanism for drug resistance. In particular
these models were used for an in-depth analysis of diﬀerent
molecular characteristics of the tumors, including EGFR
expression and activation, mutational status of KRAS, BRAF,
and NRAS, expression of EGFR ligands and activation of
HER3 (ErbB3), and hepatocyte growth factor receptor
(MET). High expression and activation of EGFR and its
ligandsepiregulinoramphiregulinwereidentiﬁedaspositive
predictive factors regulating Cetuximab response, whereas
negative factors were markers for downstream pathway acti-
vation independent of EGFR. Interestingly, overexpression
due to gene ampliﬁcation and strong activation of MET was
speciﬁcally identiﬁed in Cetuximab resistant NSCL adeno-
carcinomas [28].
4.PDXModelsofNonSmallCellLungCancer
4.1. Establishment and Preclinical Relevance. Due to its high
incidence and mortality lung cancer is the leading cause
of cancer deaths worldwide. The two major forms of lung,
cancer are non small cell lung cancer (NSCLC, about 85%
of all lung cancer) and small cell lung cancer (SCLC, about
15%). NSCLC can be divided into three major histological
subtypes: squamous cell carcinoma, adenocarcinoma, and
large cell carcinoma. Smoking is the main etiological factor
foralltypesoflungcanceralthoughitismoststronglylinked
with SCLC and squamous cell carcinoma; on the other hand
adenocarcinoma is the most common type of lung tumor in
patients who have never smoked [29, 30]. Currently most
NSCLC are diagnosed in advanced stages where ﬁve-year
survivalratesarelessthan10%.Sinceavailabletherapiesonly
provide a modest survival beneﬁt a better understanding of
the molecular basis of the disease and novel therapies are
needed to signiﬁcantly improve patients’ outcome. The
establishment of PDXs from lung cancer specimens has
therefore been investigated by us and others both as a source
of therapeutically relevant information and as a supply of
precious biological material.
After approval from the internal review board, samples
of primary non small cell lung cancer are obtained from
patients undergoing surgical resection. Each sample is
immediately cut in small pieces (25–30mm3) in antibiotic-
containing buﬀer (PBS 1x, 200U/mL penicillin, 200ug/mL
streptomycin) and implanted subcutaneously in the ﬂank
region of 4 to 6 weeks old female nude or SCID (severe
combined immunodeﬁcient) anesthetized mice. In detail,
animals are anesthetized with an intraperitoneal injection
of ketamine/xylazine/saline mixture (20:2.5:77.5v/v/v) at a
doseof10mL/kgbodyweight.Fragmentsarethenimplanted
using a trocar gauge and mice are maintained in rooms with
constant temperature and humidity (Figure 1). Tumor size
is evaluated once per week by caliper measurements and the
relative tumor weight is estimated, assuming the PDX as an
ellipsoid with a speciﬁc density of 1.0g/cm3, through the
(Lxl2)/2 (mg) formula, where L is the longest diameter and
l the shortest [31].
Typically, after a variable lag time, the tumor begins to
grow exponentially until it reaches a plateau level where the
growth slows down; it is important to transfer the tumor to a
new mouse in the period of exponential growth, mostly not
only for ethical reasons (tumor charge must never exceed
1/10 of the mouse body weight), but also because the
probability of necrotic areas within the PDX increases when
it reaches a higher mass. Highly necrotic tumors are diﬃcult
to propagate and great care should be taken to avoid this
occurrence. Successive rounds of expansion from donor toJournal of Biomedicine and Biotechnology 5
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Figure 1: Flow-chart of establishment of patient-derived xenografts. Fragments of primary tumor samples are initially implanted
subcutaneously in both ﬂanks of 1-2 immunocompromised mice, depending on tissue availability (p0). When tumors reach the exponential
growth phase they are removed from donor mice, reduced into fragments, and serially transplanted in new recipient mice (p1). For
investigational purposes (i.e., drug treatments or subpopulation analysis) PDXs can be expanded in a higher number of mice in order
to obtain statistical relevant results or suﬃcient biological material for analysis, respectively. (p: sequential passage in immunocompromised
mouse; n: number of mice.)
recipient mice can produce a sizable cohort of xenopatients
suitable for pharmacological experiments.
Each model has its speciﬁc characteristics when implant-
ed subcutaneously in diﬀerent immunodeﬁcient mouse
strains, so it is very important to monitor tumor progression
using parameters that can be useful in subsequent ex-
periments designed to evaluate the eﬀects of diﬀerent com-
pounds on individual PDXs.
The ﬁrst parameter that should be evaluated is the per-
centage of the tumor take in mice. Usually, for lung cancers
about 30–40% of the patient-derived tumors are successfully
implanted subcutaneously in nude mice. Interestingly, it
has been reported a correlation between the ability to
form PDXs and the risk of disease recurrence in early-
stage NSCLC [32]. In this study 40% of NSCLC implanted
resulted in a successful PDX with KRAS-mutated tumors
engrafting more eﬃciently than EGFR-mutated ones and
positive engraftment correlating with shorter disease-free
survival in a multivariate analysis including age, sex, stage,
and mutations.6 Journal of Biomedicine and Biotechnology
Other useful parameters are related to the growth char-
acteristics of the PDX. As previously described one feature
deﬁning PDX is its lag time before exponential growth that
can be stable or variable during subsequent passages of the
tumor. In our experience the lag time is generally higher
for the ﬁrst two-three passages and then reaches a steady
statelevel,probablyduetotheprogressivesubstitutionofthe
original human tumor stroma with murine stroma.
Beyond the lag time, the parameters to follow during
PDX establishment are speciﬁcally related to the growth
characteristics of the model: growth rate, doubling time,
time before implantation in another mouse are all useful
tools to catalogue a panel of PDX in groups with similar
characteristics. Mouse general health should also be moni-
tored during the whole process of PDX implantation. Indeed
we have observed that some tumors can induce a general
health’s worsening when implanted subcutaneously in mice
in a way reminiscent to the cachexia-inducing potential of
some human tumors. In these situations, if the growth of
the model can be supported in a diﬀerent strain, transferring
the PDX in a less immunocompromised mouse strain (i.e.,
fromSCIDtonudemice)canclearupthesekindofcachexia-
relatedissuesresulting in a fast-growing “healthy”PDX. This
could be suggestive of a higher aggressiveness of tumors with
suchfeatures,thatareprobablytooaggressivetobesustained
by an organism with a deeply compromised immune system,
but further data are needed to conﬁrm this observation.
According to our experience, PDXs can maintain the
same characteristics of the human primary tumor for several
passages (up to 20), highlighting their value as a resource
for multiple studies [33]. Since it can be very expensive
and unpractical to continuously passage PDXs in mice it is
therefore useful to set up a stock of frozen PDX samples.
A good practice is to store samples from earlier passage
and then other samples every ten–ﬁfteen passages. To obtain
successful thawing of preserved samples, freshly processed
tissue fragments should be immediately frozen in a solution
of 90% fetal bovine serum and 10% DMSO and preserved at
−80◦C.
AlsoforlungcancertherelevanceofPDXsfortheevalua-
tion of new therapeutic strategies has been reported. Patient-
derived NSCLC PDXs have been established by Fichtner
and collaborators in order to identify predictive biomarkers.
Starting from 102 surgically resected early stage (T2/T3)
NSCLCspecimens, they set up 25 transplantable PDXs. They
showed how, in early passages, PDXs maintain a high degree
of similarity with the original clinical tumor sample with
regard to histology, immunohistochemistry and mutational
status. Also the chemotherapeutic responsiveness of the
PDXs panel resembled the clinical situation. Interestingly,
they observed a correlation between KRAS mutations and
Erlotinib resistance but no correlation between anti-EGFR
therapy and mutations in EGFR or p53. Moreover, after
treatment with Cetuximab, a down regulation of EGFR was
observed in 2 of 6 sensitive PDXs but in none of the resistant
PDXs [34].
The same group used 22 well-characterized NSCLC PDX
to support the clinical development of the anticancer drug
Sagopilone (a fully synthetic low molecular weight analogue
of epothilone) involved in an integrative preclinical phase II
design. According to clinical trial criteria, 64% (14 of 22) of
lung cancer PDXs were sensible to Sagopilone. Interestingly,
tumorswithwild-type TP53aswellaswithahighexpression
of genes involved in cell adhesion/angiogenesis were more
likely to be resistant to Sagopilone. Therefore a combination
ofSagopilonewithBevacizumabandSorafenib,drugstarget-
ing vascular endothelial growth factor signaling, was tested
in Sagopilone-resistant models, restoring antitumor activity
[35].
These data conﬁrm the potential relevance of well-
annotated PDX panels to stratify the observed responses on
the basis of speciﬁc molecular alterations. This holds great
promise not only for evaluating conventional therapeutics,
butalsofortestingnoveldrugcandidatesaswellastoidentify
rationale combination therapies to be tested in clinical trials.
At the other end, for studies on personalized chemother-
apy, intended as a “quick” evaluation of the putative
treatment response of the individual patient, lung cancer
and in particular NSCLC-derived PDXs appear currently not
very suitable due to their relative low take rate (30–40%) if
implanted subcutaneously and also for the slow growth rate
(often several months). An interesting approach to bypass
these issues has been proposed by Dong and colleagues
who established PDX from 32 untreated, completely resected
patients’NSCLCs.Theyobtainedanengraftmentrateof90%
implanting small pieces of tumors under the renal capsules
of NOD/SCID mice. Treating these xenopatients with either
cisplatin + vinorelbine, cisplatin + docetaxel, or cisplatin +
gemcitabine they quickly assessed (in 6–8 weeks) the
chemosensitivity of patients’ cancers and selected the most
eﬀective regimen. Only 16 of the 32 tumors provided suﬃ-
cient tissue for testing all three chemotherapeutic regimens,
but it is noteworthy that 11 patients had adjuvant therapy
that matched the regimen used for the corresponding PDX
with good concordance between the results obtained in the
animal model and clinical response, in particular in relation
to resistance to conventional therapy (six of seven patients
who developed recurrence/metastasis during followup were
nonresponsive in mice) highlighting the need for novel
strategies[36].However,thetechniqueofengraftmentunder
the renal capsules is certainly more diﬃcult compared to
subcutaneous implantation of the tumor fragments and
NOD/SCID mice are more costly and also more diﬃcult to
breed than SCID or nude mice, which are usually utilized to
set up a PDX model.
Setting up a panel of PDX that can be used to test
new agents is costly and time and resource consuming,
moreover the selection of compounds for advancement to
human clinical trials is based, in part, on in vivo eﬃcacy
studies. It is therefore of primary importance to validate
the eﬃcacy of the PDX panel in their representation of the
human tumor. As previously mentioned, PDXs must show
histological and genetic characteristics similar to patient’s
tumors they are derived from. These characteristics should
be checked to remain unvaried after several passages in
mouse, too. Furthermore, the panel of PDXs available for
a study must be representative of the heterogeneity of the
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cancers it is mandatory to obtain a PDX panel covering all
the three major histological subtypes previously described
(i.e., squamous cell carcinoma, adenocarcinoma, and large
cell lung cancer; whereas a study on NSCLC in nonsmokers
should be mainly derived from adenocarcinomas) and to
evaluate the response to the common chemotherapeutic(s)
utilized in clinic (e.g., cisplatin), that should mimic the pa-
tients’ response tumor. These data, together with histological
and genetic characteristics, could provide the basis for a
classiﬁcation of the PDXs in groups of tumors with similar
features and similar behavior and will be very useful in
testing the activity of new compounds for NSCLC.
4.2.RelevanceforBiologicalResearch. Theavailabilityoffresh
tissue from primary human lung cancers expanded in vivo as
PDXs also constitutes an important repository of biological
material for diﬀerent studies ranging from investigation of
tumor-microenvironmentinteractiontoevaluationoftumor
heterogeneity and investigation of dynamics of diﬀerent
subpopulations during therapy.
Investigations have been carried out to deﬁne the
preservationoftissuearchitectureinPDXs,includingstroma
components and resulted in the observation of a remarkable
stability of the models even when murine cells have substi-
tutedthehumancounterpart[37,38].Ontheotherhandthe
presence of human stroma in early passages of PDXs can
be initially exploited to study interaction between tumor
cells and microenvironment. In particular studies on tumor
microenvironmentonPDXsofNSCLCatearlypassageshave
been carried out by Simpson-Abelson and collaborators.
Theyimplanted nondisrupted pieces of primary human lung
tumor in severely immunodeﬁcient mouse (NOD/SCID
IL2Rgamma null mice) obtaining PDXs in which tissue
architecture, including tumor-associated leukocytes, stromal
ﬁbroblasts, and tumor cells were preserved for prolonged
periods.Theyobservedthatplasmacellsremainedfunctional
in PDX-bearing mice, as evidenced by production of human
immunoglobulins, for up to 9 weeks after engraftment.
Moreover, tumor-associated T cells were found to migrate
from the microenvironment of the PDX to the lung, liver,
and primarily to the spleen at 8 weeks post engraftment.
These data conﬁrmed the relevance of the PDX model in
studying tumor and tumor-stromal cell interactions in situ
[39]. Interestingly the same architecture was not maintained
when tissue fragments were implanted in CB17-scid mice,
indicating once more the need to select the appropriate
model for diﬀerent biological investigations.
PDXs can also be very useful as a source of material for
studies on tumor subpopulations and their modulation after
drug treatments, leading to a more comprehensive knowl-
edge of tumor development as well as mechanisms of drug
resistance. Foci of resistant cells have been identiﬁed after
cisplatin + vinorelbine, cisplatin + docetaxel, or cisplatin +
gemcitabine treatment in responsive NSCLC PDXs by Dong
and collaborators [36]. The authors suggested that these
drug-resistant cells could be responsible for tumor recur-
rence as it frequently occurs in patients after partial or even
complete response. This observation ﬁts very well with the
hypothesis of the presence of small subpopulations of tumor
initiating cells within the tumor. This theory, known as the
cancer stem cell (CSC) theory has been proposed to explain
tumor heterogeneity and the carcinogenesis process [40,
41]. Accordingly to this model, tumor can be represented
as the result of abnormal organogenesis driven by CSCs,
deﬁnedasself-renewingtumorcellsabletoinitiatethetumor
formation and to maintain tumor heterogeneity [42, 43].
Cells with features of CSCs have been identiﬁed in acute
myeloid leukemia [44], glioblastoma [45–47], melanoma
[48, 49], and diﬀerent epithelial cancers [50–56].
Twomaintechniquesaregenerallyusedtoidentifytumor
initiating cells: (i) prospective ﬂow cytometry-based cell
sorting using tissue-speciﬁc surface markers or (ii) sphere
forming assays in selective cells culture medium. Due to the
relative paucity of the cancer stem cell fraction in the tumor
population it is highly desirable to have a substantial amount
of tumor samples available for thorough investigation but
this is not easily obtained from surgical specimens. Since
human cancer PDX models are similar to the patients’
tumors not only in terms of genetic, immunohistochemical,
and microenvironment features but also in terms of hetero-
geneity of the tumor cellular composition they are a useful
modelalsoinstudiesofsubpopulations withcancerstemcell
characteristics(Figure 2).Asamatteroffactthepossibilityto
expand the patient-derived tumor in immunocompromised
mice yields a large amount of material for studies such as
ﬂow cytometry-based cell sorting. Using this approach our
group has recently been successful in identifying a highly
tumorigenic CD133+ subpopulation in non small cell lung
cancers which displays stem-like features and is spared by
cisplatin treatment [33, 57].
PDXs as a tool for CSC studies have been also devel-
oped for pancreatic cancer. Jimeno et al. showed that the
chemotherapeutic treatment of pancreatic PDXs resulted in
an increase of CSC markers (ALDH and CD24), in the resid-
ual tumor population, supporting the idea of an enhanced
chemoresistance of the cancer stem cells subpopulation.
Moreover, the authors showed that CSCs targeting could
increase the eﬃcacy of conventional treatment. Combining
gemcitabine with an inhibitor of the hedgehog pathway, that
is fundamental for the maintenance of CSCs, they induced
tumorregressionandadecreaseinCSCfraction[58].Similar
results were obtained with PDXs derived from other cancer
types [59, 60], suggesting that combination therapy using
conventional chemotherapy and drugs against CSC speciﬁc
targets can lead to better therapeutic results, both in terms of
t u m o rg r o w t ha sw e l la si nt e r m so rt u m o rr e l a p s e .
Furthermore, subpopulations isolated from expanded
PDXs can also be studied in vivo if reinjected in immuno-
compromised mice and their characteristics in terms of
tumorigenicity as well as in term of response to chemother-
apeutics can be directly compared with the characteristics
of the parental tumor. This gives the possibility to identify
treatment resistant subpopulations and to study the tumori-
genic potential of prospectively identiﬁed putative CSCs.
The relevance of these models in identifying and isolating
CSC subpopulation has been proved also for other cancer8 Journal of Biomedicine and Biotechnology
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Figure 2: Frequency of CD133+ cells in primary tumors is maintained in PDXs during passaging in mice independently of their initial
content. Dot plots showing that the percentage of CD133+ cells, previously demonstrated to display stem-like features and to be spared
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(50μg/mL; AC133 clone; Miltenyi Biotech).
types, such as breast cancer [60], colon carcinoma [61], and
pancreatic adenocarcinoma [62, 63].
5. ConclusiveRemarks
A growing number of research groups have established
panels of patient-derived xenografts, demonstrating their
relevance in drug development studies as well as in the
discovery of novel predictive biomarkers to be used in the
clinical setting.
It is therefore of primary importance to set up panels
of PDXs highly representative of the cancer type under in-
vestigation and to validate the models through extensive
immunohistochemical and genetic characterization to con-
ﬁrm similarities with the human tumor and also in terms
of response to common chemotherapeutics to conﬁrm the
robustness of the model in testing the eﬃcacy of new
treatments. In our experience, growth features of PDX such
as lag time and growth rate reach stability after two-three
passages in mouse; it is therefore advisable to carry out drug
eﬃcacy tests with PDXs that have reached a certain stability
in their growth characteristics.
This kind of preclinical model is also exploitable in
researchﬁelds suchastumor-microenvironment interaction,
cancer stem cells identiﬁcation and modulation after drug
treatment. Human cancer PDXs are particularly suitable for
this kind of research because they provide a large amountJournal of Biomedicine and Biotechnology 9
of material reproducing the original human tumor and its
microenvironment and could therefore be more extensively
utilized not only in preclinical studies but also in basic
research. However, it is always noteworthy to remember
that when using animal models for biological purposes,
the guidelines for the welfare and use of animals in cancer
research should be always kept in mind and strictly followed
[64].
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